ライフサイエンスコーパス: preexposure

1 y LPS was also robustly increased by ethanol preexposure.

2 rived epithelial cells on diethylstilbestrol preexposure.

3 ecessary for mice to benefit from contextual preexposure.

4 n of delay but not trace relative to context preexposure.

5 ected only when TNF treatment followed 17AAG preexposure.

6 APV blocked the facilitatory effect of preexposure.

7 (APV) on the facilitatory effect of context preexposure.

8 nipple (no fluid), both 1 hr and 24 hr after preexposure.

9 om sera with neither H1 nor type B influenza preexposure.

10 traces and consequent trace dominance after preexposure.

11 Blood neutrophils increased from preexposure (34.4% +/- 0.13%) to 48 h (75.6% +/- 0.08%)

12 Following preexposure, all rats received pairings of A and a foots

13 human postvaccination sera with H1 influenza preexposure also correlated poorly with those derived fr

14 We suggest that multimodal preexposure alters the circuitry responsible for object

15 s: group I consisted of 92 serum samples (10 preexposure and 82 postexposure serum samples) from 10 a

16 Because rats learn about the context during preexposure and express that learning after being reinfo

17 Preexposure and follow-up studies of symptoms, leukocyte

18 S a promising vaccine candidate for both the preexposure and postexposure prophylaxis of rabies.

19 After stimulus preexposure and unpaired training sessions with a tone c

20 HSV is inactivated by low-pH preexposure, and gB, a class III fusion protein, undergo

21 om sera with neither H1 nor type B influenza preexposure, and the correlation lessened considerably o

22 or the proportion of measles cases that had preexposure antibody concentrations above a threshold of

23 The studies reported either preexposure antibody concentrations of individuals along

24 In the PFC, we also find that WIN preexposure blunts the typical mRNA response to cocaine

25 Following CS preexposure, both the preexposed CS and a control CS pre

26 ETI-204 administered preexposure by a single intravenous injection of a dose

27 zed, controlled trial showed that daily oral preexposure chemoprophylaxis (PrEP) was effective for HI

28 ylaxis Initiative (iPrEx), a global trial of preexposure chemoprophylaxis against human immunodeficie

29 Preexposure chemoprophylaxis in only high-risk MSM can i

30 gnificant dose-response relationship between preexposure cognitive ability and risk for PTSD.

31 Genetic influences on preexposure cognitive ability explained 5% of the variat

32 Preexposure cognitive ability is a risk or a protective

33 The variance in PTSD explained by preexposure cognitive ability is accounted for entirely

34 termine, in a representative sample, whether preexposure cognitive ability is associated with risk fo

35 o potentially traumatic events and underwent preexposure cognitive testing.

36 Subjects experienced 1 of 3 preexposure conditions (paired CS-US, unpaired CS-US, or

37 nditioned and unconditioned stimulus (CS-US) preexposure conditions on learning at different ages.

38 ropensity score matching to control for >120 preexposure confounders.

39 tvaccination sera with only type B influenza preexposure consistently showed good correlation with th

40 n cultures after neutrophil exposure than in preexposure cultures.

41 There were no significant post- and preexposure differences in cotinine levels after control

42 velopment of FILORAB1/GLA-SE as an effective preexposure EBOV vaccine.

43 learning after being reinforced, the context preexposure effect is an aversive analogue of latent lea

44 Taking advantage of the ISD and the context preexposure effect, the authors found that animals preex

45 Furthermore, preexposure enhanced conditioning to an immediate footsh

46 e the introduction of artificial nests (odor preexposure), enhanced the survival of birds eggs (prey)

47 members has begun; and 2) analytically, the preexposure experience is combined with that which takes

48 Paired preexposure facilitated acquisition of delay but not tra

49 oning to an immediate footshock, the context preexposure facilitation effect (CPFE), but had no effec

50 g apart, the authors made use of the context preexposure facilitation effect (CPFE).

51 jected with BrdU were tested for the context preexposure facilitation effect (CPFE; ~PD117).

52 The authors used 3-phase context preexposure facilitation methodology to study the contri

53 Postexposure and preexposure geometric mean salivary cotinine concentrati

54 These data suggest that preexposure history and deceptive imprinting may complic

55 ndomized trial of antiretroviral therapy for preexposure HIV-1 prophylaxis among men who have unprote

56 tential public health impact that imperfect, preexposure HSV-2 vaccines could have on reducing the in

57 Designing preexposure HSV-2 vaccines with therapeutic characterist

58 diated dilation (FMD) of the brachial artery preexposure, immediately postexposure, and 20 hr postexp

59 After adjustment for preexposure immunity, the overall secondary attack rate

60 Unpaired preexposure impaired acquisition of both delay and trace

61 spartate (NMDA) receptor inactivation during preexposure impairs contextual learning at PND 23.

62 In addition, context preexposure increased fear conditioning in males and dec

63 Reversible inactivation during taste preexposure increased FLI to familiar taste pairing in a

64 sion onto VTA dopamine neurons after cocaine preexposure is likely to produce an abnormal increase in

65 wild-type plants was partly restored to the preexposure level by 5 mm Ca(NO(3))(2) and protein phosp

66 ry NNAL concentrations also were higher than preexposure levels following bar and restaurant visits [

67 Techniques based on olfactory preexposure may provide prey with protection during crit

68 After 2 days of preexposure measurements, volunteers were inoculated wit

69 Further, D-serine preexposure occluded AP5 inhibition of mPFC-evoked EPSCs

70 Finally, preexposure of A. fumigatus, but not S. prolificans, to

71 Preexposure of BLMVECs to physiological steady laminar f

72 ace density whereas stimulation is lost with preexposure of cells to the surface-SERT inactivating re

73 In vitro studies revealed that preexposure of cells with thymoquinone (25 mumol/L) for

74 Preexposure of ch1 plants to moderately elevated light i

75 Preexposure of eyes to bacteria did not enhance clearanc

76 ine-evoked WPB exocytosis was not changed by preexposure of HAECs to physiologic saline, U9F4, or W6/

77 We found that preexposure of healthy PBMCs to HCV viral particles atte

78 Preexposure of healthy peripheral blood mononuclear cell

79 It is well established that preexposure of human neutrophils to proinflammatory cyto

80 Preexposure of isolated virions to mildly acidic pH of 5

81 Furthermore, preexposure of LC to L3 did not alter Toll-like receptor

82 Specifically, preexposure of mice to subthreshold doses of TNF, which

83 Preexposure of MTS-reactive mutants S047C (TM I) and T06

84 In this study, tolerance induction by preexposure of murine macrophages to Toll-like receptor

85 Preexposure of nematodes to Bacillus subtilis did not pr

86 Our study shows that preexposure of Pinus sylvestris to pine sawfly sex phero

87 Preexposure of several MTS-sensitive mutants in TMs V, V

88 Preexposure of SKOV-3 cells to caffeine, a competitive i

89 However, preexposure of SKOV-3 cells to dipyridamole, an equilibr

90 se cells with RANKL activated NF-kappaB, and preexposure of the cells to curcumin completely suppress

91 dation of behavioral conditioning because of preexposure of the conditional stimulus (CS).

92 o elucidate the effects of age and influenza preexposures on cross-reactivity of vaccination-induced

93 inistered into the hippocampus after context preexposure or contextual fear conditioning impaired sub

94 pocampus (VH) with muscimol prior to context preexposure or injecting anisomycin into the VH after pr

95 Distinct behavioural manipulations-context preexposure or interference during memory retrieval-diff

96 Preexposure or long-term exposure of VAChT to high pH do

97 2, rabbits were given 0, 4, or 8 days of CS preexposures or context-alone experience.

98 801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory condition

99 nditioning as a consequence of nonreinforced preexposure (PE) of the future conditioned stimulus.

100 The preexposure period included January 1, 2008, through Dec

101 ither the DH or BLA prior to (a) the context preexposure phase, (b) the immediate shock phase, or (c)

102 Conversely, in the CMOR task with preexposure, PPC lesions had no effect, whereas PRh invo

103 h clinical site and test operator (P < .05), preexposure prophylaxis (P = .01), low plasma viral load

104 With the introduction of preexposure prophylaxis (PrEP) against HIV, we hypothesi

105 The use of antiretrovirals for preexposure prophylaxis (PrEP) among high-risk persons w

106 We examined the cost-effectiveness of both preexposure prophylaxis (PrEP) and HIV testing strategie

107 Preexposure prophylaxis (PrEP) and postexposure prophyla

108 virine (RPV LA) has been proposed for use as preexposure prophylaxis (PrEP) and the prevalence of tra

109 Preexposure prophylaxis (PrEP) and treatment as preventi

110 ther TDF causes tubulopathy when used as HIV preexposure prophylaxis (PrEP) and whether tubulopathy p

111 virus infection (HIV)-infected patients and preexposure prophylaxis (PrEP) as a prevention option fo

112 Antiretroviral therapy (ART) used as preexposure prophylaxis (PrEP) by human immunodeficiency

113 ion of rilpivirine (TMC278LA) is a promising preexposure prophylaxis (PrEP) candidate for prevention

114 lines for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) developed by the US Cente

115 he feasibility, acceptability, and safety of preexposure prophylaxis (PrEP) for black men who have se

116 Data on effectiveness of preexposure prophylaxis (PrEP) for human immunodeficienc

117 Referrals for and initiation of preexposure prophylaxis (PrEP) for human immunodeficienc

118 ble discussion and debate about adherence to preexposure prophylaxis (PrEP) for human immunodeficienc

119 Pharmacological studies in the context of preexposure prophylaxis (PrEP) for human immunodeficienc

120 rilpivirine (RPV) could promote adherence to preexposure prophylaxis (PrEP) for human immunodeficienc

121 population health benefits and costs of HIV preexposure prophylaxis (PrEP) for people who inject dru

122 Antiretroviral preexposure prophylaxis (PrEP) for persons at high risk

123 Recent studies show the promise of preexposure prophylaxis (PrEP) for preventing HIV infect

124 Given that preexposure prophylaxis (PrEP) has been shown to be effi

125 Oral antiretroviral preexposure prophylaxis (PrEP) has been shown to decreas

126 Although preexposure prophylaxis (PrEP) has demonstrated effectiv

127 Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has great potential to re

128 Use of HIV preexposure prophylaxis (PrEP) has increased nationwide,

129 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency

130 roxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States.

131 Expanding use of preexposure prophylaxis (PrEP) in ways that address curr

132 represent a key population for implementing preexposure prophylaxis (PrEP) interventions worldwide,

133 Preexposure prophylaxis (PrEP) involves use of antiretro

134 Preexposure prophylaxis (PrEP) is a promising approach t

135 xil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective strategy

136 Preexposure prophylaxis (PrEP) is effective for preventi

137 Preexposure prophylaxis (PrEP) is highly effective for p

138 One barrier to human immunodeficiency virus preexposure prophylaxis (PrEP) is lack or perceived lack

139 uman immunodeficiency virus (HIV) infection, preexposure prophylaxis (PrEP) is one of the few effecti

140 an objective measure to monitor adherence to preexposure prophylaxis (PrEP) or TFV-based antiretrovir

141 to describes trends in prescriptions for HIV preexposure prophylaxis (PrEP) overall and by specialty

142 d tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acqu

143 The CAPRISA 004 preexposure prophylaxis (PrEP) randomized trial demonstr

144 nondaily human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) regimens among high-risk

145 HIV-testing algorithms for preexposure prophylaxis (PrEP) should be optimized to mi

146 tudies on treatment as prevention (TasP) and preexposure prophylaxis (PrEP) show that antiretroviral

147 tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 we

148 the efficacy of several antiretroviral-based preexposure prophylaxis (PrEP) strategies being tested.

149 FACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vag

150 delines about the daily use of medication as preexposure prophylaxis (PrEP) to prevent HIV infection.

151 ormulation (RPV LA) to improve adherence for preexposure prophylaxis (PrEP) to prevent HIV-1 transmis

152 ntial for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) to reduce the racial disp

153 ciated with syphilis infection within an HIV preexposure prophylaxis (PrEP) trial and whether emtrici

154 udy participants are increasingly popular in preexposure prophylaxis (PrEP) trials, since they provid

155 egative, we compared observed concordance in preexposure prophylaxis (PrEP) use with the counterfactu

156 Daily oral preexposure prophylaxis (PrEP) using the antiretroviral

157 d identify women who would most benefit from preexposure prophylaxis (PrEP) while minimizing unnecess

158 pletely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containi

159 Preexposure prophylaxis (PrEP) with antiretroviral drugs

160 Preexposure prophylaxis (PrEP) with antiretrovirals (ARV

161 rial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtricitabine (FTC)

162 Preexposure prophylaxis (PrEP) with emtricitabine plus t

163 Daily preexposure prophylaxis (PrEP) with emtricitabine/tenofo

164 Daily preexposure prophylaxis (PrEP) with oral emtricitabine a

165 odeficiency virus (SIV/SHIV) exposure during preexposure prophylaxis (PrEP) with oral tenofovir can i

166 HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtri

167 Preexposure prophylaxis (PrEP) with tenofovir disoproxil

168 Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabi

169 infected partner in a serodiscordant couple, preexposure prophylaxis (PrEP), prevention of mother-to-

170 Antiretroviral preexposure prophylaxis (PrEP), using daily oral combina

171 Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoprox

172 phoma and 8 HIV-uninfected men receiving HIV preexposure prophylaxis (PrEP), we performed KSHV typing

173 Preexposure prophylaxis (PrEP), which emerged in recent

174 idence was determined in HIV-infected and in preexposure prophylaxis (PrEP)-using MSM.

175 ase adherence problems associated with daily preexposure prophylaxis (PrEP).

176 or men who have sex with men (MSM) using HIV preexposure prophylaxis (PrEP).

177 HIV prevention, including implementation of preexposure prophylaxis (PrEP).

178 partner notification, promoting condoms, and preexposure prophylaxis (PrEP).

179 y interact with human immunodeficiency virus preexposure prophylaxis (PrEP).

180 and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).

181 Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP).

182 effective human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP).

183 ssive transfer of antibody may be useful for preexposure prophylaxis against biological agents used a

184 F-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women

185 These data support MK-8591's potential as a preexposure prophylaxis agent.

186 ntibody-based oral, topical, and/or systemic preexposure prophylaxis agents and provide guidance in t

187 al of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1-serodiscordant heter

188 ve relevance for trials of maraviroc for HIV preexposure prophylaxis and graft-versus-host disease.

189 itized for delivery of interventions such as preexposure prophylaxis and individualized counseling on

190 on of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose m

191 immediate treatment) and PrEP (initiation of preexposure prophylaxis by high-risk uninfected individu

192 -prevalence populations and in persons using preexposure prophylaxis for HIV prevention.

193 toxicity may reduce the efficacy of topical preexposure prophylaxis for human immunodeficiency virus

194 ion of these antibodies could be employed as preexposure prophylaxis for Lyme disease.

195 ofovir disoproxil fumarate is recommended as preexposure prophylaxis for persons at high risk for HIV

196 Antiretroviral preexposure prophylaxis has been shown to reduce the ris

197 promise of this strategy, clinical trials of preexposure prophylaxis have had limited degrees of succ

198 ng antibodies should be evaluated for use as preexposure prophylaxis in clinical trials.

199 acokinetic data, the DPV VR is promising for preexposure prophylaxis in postmenopausal women.

200 We assessed MK-8591 as preexposure prophylaxis in the rhesus macaque model of i

201 The Preexposure Prophylaxis Initiative (iPrEx) chemoprophyla

202 The Preexposure Prophylaxis Initiative (iPrEx) study randoml

203 ublished data from 2 PrEP trials, namely the Preexposure Prophylaxis Initiative (iPrEx) trial and the

204 d using subgroup efficacy estimates from the preexposure prophylaxis initiative (iPrEx) trial.

205 We leveraged data from the Preexposure Prophylaxis Initiative (iPrEx), a global tri

206 eduction derived from PBMCs collected in the preexposure prophylaxis initiative study was used to cal

207 Topical preexposure prophylaxis interrupts HIV transmission at t

208 Antiretroviral preexposure prophylaxis is a promising approach for prev

209 We found that preexposure prophylaxis is most cost-effective when targ

210 Preexposure prophylaxis programs involve frequent human

211 Preexposure prophylaxis should be considered as part of

212 nal postexposure prophylaxis; ongoing use of preexposure prophylaxis should be guided by regular risk

213 cessible, inexpensive, and female-controlled preexposure prophylaxis strategies to prevent mucosal tr

214 indings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in

215 We piloted PrEP@Home, a preexposure prophylaxis system of remote laboratory and

216 extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men.

217 rate/emtricitabine is recommended for use as preexposure prophylaxis to prevent HIV infection in pers

218 We reviewed data from an HIV preexposure prophylaxis trial to determine if tenofovir

219 ovide data for guidelines for US women's HIV preexposure prophylaxis use.

220 For individuals at risk for HIV, preexposure prophylaxis with an oral regimen is recommen

221 Preexposure prophylaxis with antiretroviral agents has b

222 Preexposure prophylaxis with antiretroviral drugs has be

223 Preexposure prophylaxis with F/TAF versus F/TDF.

224 ge to care (including transition from PEP to preexposure prophylaxis); and (3) randomized controlled

225 rated protection from HIV infection with ART preexposure prophylaxis, and several clinical trials are

226 to local HIV prevention services, including preexposure prophylaxis, compared with those who underwe

227 resources and target interventions, such as preexposure prophylaxis, to MSM at greatest risk of acqu

228 low-up, tenofovir can be used safely for HIV preexposure prophylaxis.

229 al lectin and is being developed for topical preexposure prophylaxis.

230 tion, including treatment for prevention and preexposure prophylaxis.

231 al agents that has recently shown promise as preexposure prophylaxis.

232 and other HIV prevention strategies, such as preexposure prophylaxis.

233 ho have sex with men who were not using oral preexposure prophylaxis.

234 r suppression of viral shedding or effective preexposure prophylaxis.

235 ese data support lamivudine as an option for preexposure prophylaxis.

236 daily use of oral and vaginal TFV for HIV-1 preexposure prophylaxis.

237 y about risk reduction strategies, including preexposure prophylaxis.

238 e 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis.

239 al (ID) administration of rabies vaccine for preexposure prophylaxis.

240 ing or sustained delivery may be optimal for preexposure prophylaxis.

241 ore HIV exposure to prevent infection (i.e., preexposure prophylaxis; PrEP) is under evaluation in cl

242 ntensive pharmacokinetic study ("Cell-PrEP" [preexposure prophylaxis]) of 30 days of daily TDF/FTC fo

243 that antibodies and antiretrovirals mediate preexposure protection in this mouse model and that the

244 Although, during preexposure, pups responded most positively to the nippl

245 The existing 4-week preexposure rabies vaccination schedule is costly and of

246 exts used and further indicated that context preexposures reduce acute HPA axis responses to loud noi

247 g muscimol, a GABAA agonist, before or after preexposure reduced this effect.

248 In the original CMOR task, with no preexposure, reversible lesions of PRh or PPC produced p

249 Results comparing next-day and preexposure salivary cotinine levels were similar.

250 A longitudinally sampled cohort with preexposure sampling is needed to validate our results.

251 re or injecting anisomycin into the VH after preexposure significantly impaired rats' memory for cont

252 Preexposure therapy with CpG ODNs may protect victims of

253 require PRh activity when rats did not have preexposure; this pattern was supported by results from

254 the enhanced liver damage caused by ethanol preexposure; this protection correlated with a significa

255 tion identified symptomatic individuals with preexposure titers exceeding this threshold.

256 Preexposure to a low concentration of glucose upregulate

257 Preexposure to a nipple providing ethanol or saccharin (

258 Furthermore, preexposure to AdHu5 affects long-term alterations in th

259 e poorly understood, one possibility is that preexposure to alloantigen results in the induction of r

260 exhibited enhanced response magnitudes after preexposure to an intermediate hyperosmotic stress.

261 ated hyphal damage occurring with or without preexposure to caspofungin or with preexposure to the co

262 We report here that, in parkinsonian rats, preexposure to chronic levodopa significantly reduces be

263 rease in GLT-1 activity that is prevented by preexposure to either Bis II or hypertonic treatment.

264 Preexposure to exogenous insulin increased the endogenou

265 Despite preexposure to high concentrations of toxin A for 3 h, c

266 erweight/obese subjects with asthma and that preexposure to high-dose leptin enhanced the proinflamma

267 isms of tolerance, we examined the effect of preexposure to LPS on activation of p38, c-Jun, and NF-k

268 AM expression was inhibited significantly by preexposure to normal shear stress.

269 ors resisted both the suppressive effects of preexposure to poly(I .

270 We demonstrated that their preexposure to Pseudomonas aeruginosa flagellin modify t

271 s to TA and OA selectively desensitize after preexposure to the amines.

272 This phenomenon was replicated by exogenous preexposure to the amino acid D-aspartate (D-Asp).

273 r without preexposure to caspofungin or with preexposure to the combination of caspofungin and anti-b

274 single-trial CFC can be rescued by providing preexposure to the conditioning context.

275 ion immediately prior to the shock or during preexposure to the context at an earlier time.

276 Preexposure to the context in the absence of shock, coup

277 Here, we demonstrate that preexposure to the green leaf volatile Z-3-hexenyl aceta

278 irst encounter with cocaine, with or without preexposure to the synthetic cannabinoid WIN 55,212-2 (W

279 onse produced by the repeated nonrein-forced preexposure to the to-be-conditioned stimulus.

280 ication of the CMOR task in which multimodal preexposure to the to-be-remembered objects significantl

281 Our results show that preexposure to the vector substantially diminishes the t

282 )-based model of massive liver repopulation, preexposure to this naturally occurring alkaloid is suff

283 Furthermore, preexposure to uncontrollable (noncontingent) shock to t

284 d the size of these preferences, but neither preexposure to unflavored caffeine nor hunger during the

285 Here, however, human neutrophil preexposure to uniform shear stress (0.1-2.75 dyn/cm(2))

286 istributions of kexp captured the effects of preexposure to UV light.

287 nts, involving genes such as Npas2 Moreover, preexposure to WIN enhances the effects of cocaine on pr

288 that in adolescent (but not in adult) rats, preexposure to WIN results in cross-sensitization to coc

289 r vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS).

290 ause of lack of adherence to the recommended preexposure treatment regimens.

291 Preexposure tuberculosis vaccination, including revaccin

292 who should not receive smallpox vaccine in a preexposure vaccination campaign.

293 According to current recommendations, a preexposure vaccination program should identify these pe

294 Rabies is a deadly disease, and current preexposure vaccination schedules are lengthy and expens

295 We modeled the future impact of preexposure vaccines with both prophylactic and therapeu

296 at challenge macaque model and showed that a preexposure vaginal application of gel with 1% TFV alone

297 ement of LPS-induced liver damage by ethanol preexposure was associated with unique protein changes.

298 CpG preexposure was protective against enhanced disease duri

299 en preexposure was to both A and B than when preexposure was to B only.

300 Sham rats' generalization was greater when preexposure was to both A and B than when preexposure wa